Symbiosis Pharmaceutical Services

The business model centers on providing sterile fill/finish services for vials, catering to clients developing drugs for clinical trials and low-volume commercial markets. Symbiosis specializes in handling complex biologics, including monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), viral vectors for gene therapies, and small molecule drugs in both liquid and lyophilized (freeze-dried) forms. Its services are designed to accelerate drug development timelines by offering quick access to manufacturing slots and expedited product release. The company primarily serves biotechnology and pharmaceutical companies, with over 80% of its client base located in the US and Europe.

A significant milestone for the company was its role in manufacturing the Oxford University/AstraZeneca COVID-19 vaccine for clinical trials. The company has steadily expanded its capabilities, adding BSL-2 manufacturing suites, in-house quality control labs for analytical and microbiological testing, and temperature-controlled stability storage. Symbiosis has also received multiple rounds of funding, including grants from Innovate UK and debt financing from Allied Irish Bank (AIB), to support its growth and expansion of facilities. By July 2025, the company had successfully completed its 1,000th sterile drug product batch, and in the same year, received the King's Award for Enterprise for International Trade.